Cargando…
Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening
The performance of cervical cancer screening will decline as a function of lower disease prevalence—a consequence of successful human papillomavirus (HPV) vaccination. Replacement of cytology with molecular HPV testing as the primary screening test and adoption of risk‐based screening, with less int...
Autores principales: | Tota, Joseph E., Isidean, Sandra D., Franco, Eduardo L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689748/ https://www.ncbi.nlm.nih.gov/pubmed/32588426 http://dx.doi.org/10.1002/ijc.33178 |
Ejemplares similares
-
HPV and cervical cancer: screening or vaccination?
por: Bosch, F X, et al.
Publicado: (2008) -
Cervical Cancer Screening and HPV Vaccination in Nepal
por: Baral, Gehanath, et al.
Publicado: (2023) -
Proposal for cervical cancer screening in the era of HPV vaccination
por: Ouh, Yung-Taek, et al.
Publicado: (2018) -
Erratum: Cervical Cancer Screening and HPV Vaccination in Nepal
por: Baral, Gehanath, et al.
Publicado: (2023) -
Prevention of Cervical Cancer through HPV Vaccination and Screening in Maldives
por: Mullapally, Sujith Kumar, et al.
Publicado: (2023)